# Modeling immunity to malaria with an age-structured PDE Framework

## Zhuolin Qu

Department of Mathematics University of Texas at San Antonio

Denis Patterson<sup>1</sup> Lauren Childs<sup>2</sup> Christina Edholm<sup>3</sup> Joan Ponce<sup>4</sup> Olivia Prosper<sup>5</sup> Lihong Zhao<sup>6</sup>

<sup>1</sup> Princeton University <sup>2</sup> Virginia Tech <sup>3</sup> Scripps College <sup>4</sup> University of California, Los Angeles
 <sup>5</sup> University of Tennessee, Knoxville <sup>6</sup> University of California Merced

This research is based upon work supported by the National Science Foundation under Grant Number DMS 1641020, and the UTSA New Faculty Startup Funds.

#### Outlines

#### Introduction of malaria

2 Mathematical modeling of malaria with immunity

3) Basic reproduction number  $\mathcal{R}_0$ 

4 Numerical examples

Zhuolin Qu (UTSA)

イロト イボト イヨト イヨト

- Severe public health problems worldwide for a long time
- about 229 million cases and 409K people died worldwide (2019)
- poverty, economic development
- children (age < 5) give 2/3 of fatalities, African region



Source: Our World in Data, Data: Institute for Health Metrics and Evaluation (IHME), 2018. 🗇 🖂 🗄 🛌 🗧 🖉 🔍 🔍

• mosquito-borne disease

vector: *Anopheles* mosquitoes (exclusively) parasites: *Plasmodium falciparum* (Africa, deadliest)

э

< ロ > < 同 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 > < 0 >

mosquito-borne disease

vector: *Anopheles* mosquitoes (exclusively) parasites: *Plasmodium falciparum* (Africa, deadliest)

malaria controls

insecticide-treated nets, indoor residual spraying antimalarial drug (drug resistance), Intermittent preventive therapy vaccine (RTS,S)



Source: MalariaWorld, USAID, WHO

Zhuolin Qu (UTSA)

< □ > < 同 > < 回 > < 回 > < 回 >

mosquito-borne disease

vector: *Anopheles* mosquitoes (exclusively) parasites: *Plasmodium falciparum* (Africa, deadliest)

malaria controls

insecticide-treated nets, indoor residual spraying antimalarial drug (drug resistance), Intermittent preventive therapy vaccine (RTS,S)



#### Better understand the disease dynamics - heterogeneity!

Source: MalariaWorld, USAID, WHO

Zhuolin Qu (UTSA)

< □ > < 同 > < 回 > < 回 > < 回 >

## Heterogeneity in malaria infection

Natural immunity to malaria can be acquired through repeated exposure.

- Age-related prevalence and immune profiles
- Vary with environment different transmission level
- Low transmission region: flat profile
- High transmission region: peak in young children
- Seasonality (temperature, humidity), elevation



Filipe J et al, 2007, PLOS Computational Biology 3(12): e255, https://doi.org/10.1371/journal.pcbi.0030255 💿 🐑 🔍

Zhuolin Qu (UTSA)

## Heterogeneity in malaria infection

#### Develop model to capture the heterogeneity in

- Age-related prevalence and immune profiles
- Vary with environment different transmission level
- Low transmission region: flat profile
- High transmission region: peak in young children
- Seasonality (temperature, humidity), elevation



Filipe J et al, 2007, PLOS Computational Biology 3(12): e255, https://doi.org/10.1371/journal.pcbi.0030255 💿 🕤 🗠

Zhuolin Qu (UTSA)

#### Malaria PDE with immunity

3/25

#### Outlines

#### Introduction of malaria

#### 2 Mathematical modeling of malaria with immunity

3 Basic reproduction number  $\mathcal{R}_0$ 

#### 4 Numerical examples

э

イロト イボト イヨト イヨト

#### Human-mosquito transmission model



A B b A B b

#### Human-mosquito transmission model



・ 何 ト ・ ヨ ト ・ ヨ ト

#### Human-mosquito transmission model





- What to track?
- anti-disease immunity: clinical symptoms, e.g.  $E_H \rightarrow D_H$ ?
- anti-parasite immunity: parasite clearance, e.g. recovery rates r<sub>A</sub>, r<sub>D</sub>

< □ > < □ > < □ > < □ > < □ > < □ >



- What to track?
- anti-disease immunity: clinical symptoms, e.g.  $E_H \rightarrow D_H$ ?
- anti-parasite immunity: parasite clearance, e.g. recovery rates  $r_A$ ,  $r_D$

< □ > < □ > < □ > < □ > < □ > < □ >



- What to track?
- anti-disease immunity: clinical symptoms, e.g.  $E_H \rightarrow D_H$ ?

 $\rho$ : *Prob* ( $E_H \rightarrow D_H$ ) exposure  $\rightarrow$  severe disease

- $\psi$ : Prob ( $A_H \rightarrow D_H$ ) "superinfection"  $\rightarrow$  severe disease
- $\phi$ : *Prob*  $(D_H \rightarrow S_H)$  severe disease  $\rightarrow$  fully recover



- What to track?
- anti-disease immunity: clinical symptoms, e.g.  $E_H \rightarrow D_H$ ?
- three different sources

< □ > < □ > < □ > < □ > < □ > < □ >



- What to track?
- anti-disease immunity: clinical symptoms, e.g.  $E_H \rightarrow D_H$ ?
- three different sources
  - $C_{\nu}$  immunity boosting vaccine (blood-stage vaccine)
  - $V_H$  infection protection vaccine (RTS,S)

< □ > < □ > < □ > < □ > < □ > < □ >

#### Tracking the population immunity - different sources

$$\begin{aligned} & \underbrace{C_{e}(\alpha, t)}_{immunity acquised immunity for people age}_{immunity acquision (exposure)} age = \alpha \\ & \underbrace{\frac{\partial C_{e}}{\partial t} + \frac{\partial C_{e}}{\partial \alpha}}_{immunity acquision (exposure)} = \underbrace{f(\Lambda_{H}) \left(c_{S}S_{H} + c_{E}E_{H} + c_{A}A_{H} + c_{D}D_{H}\right)}_{expansion} \\ & \underbrace{C_{e}(0, t) = 0}_{f(\Lambda_{H}) = \frac{\Lambda_{H}}{\gamma\Lambda_{H} + 1}, \quad \gamma \ge 0 \quad \begin{array}{c} \text{Saturation} \\ \text{function} \end{array} \quad \begin{array}{c} \underbrace{C_{e}}_{de} - \underbrace{\mu_{H}(\alpha)C_{e} - \mu_{D}(\alpha)\frac{D_{H}}{P_{H}}C_{e}}_{(natural)} \\ & (disease) \end{array} \end{aligned}$$

 $P_H(\alpha, t) = S_H + E_H + A_H + D_H + V_H$ 

#### Tracking the population immunity - different sources

$$\begin{aligned} C_{e}(\alpha, t): & \text{exposure-acquired immunity for people age} = \alpha \\ & \underset{\text{immunity acquision (exposure)}}{\frac{\partial C_{e}}{\partial t} + \frac{\partial C_{e}}{\partial \alpha}} = \boxed{f(\Lambda_{H}) (c_{S}S_{H} + c_{E}E_{H} + c_{A}A_{H} + c_{D}D_{H})} \\ & \underset{\text{waning}}{\text{waning}} \qquad \text{loss from death} \\ C_{e}(0, t) = 0 \\ & f(\Lambda_{H}) = \frac{\Lambda_{H}}{\gamma\Lambda_{H} + 1}, \quad \gamma \ge 0 \quad \underset{\text{function}}{\text{Saturation}} \qquad - \frac{C_{e}}{d_{e}} - \underbrace{\mu_{H}(\alpha)C_{e} - \mu_{D}(\alpha)\frac{D_{H}}{P_{H}}C_{e}}_{\text{(natural)} \text{ (disease)}} \\ P_{H}(\alpha, t) = S_{H} + E_{H} + A_{H} + D_{H} + V_{H} \end{aligned}$$

$$C_{m}(\alpha, t): \text{ maternal-derived immunity for people age} = \alpha \\ \frac{\partial C_{m}}{\partial t} + \frac{\partial C_{m}}{\partial \alpha} = - \underbrace{C_{m}}_{d_{m}} - \underbrace{\mu_{H}(\alpha)C_{m} - \mu_{D}(\alpha)\frac{D_{H}}{P_{H}}C_{m}}_{\text{(natural)} \text{ (disease)}} \\ C_{m}(0, t) = m_{0} \int_{0}^{\infty} \underbrace{\underset{g_{H}(\alpha)}{\text{birth}} (c_{1}C_{e}(\alpha, t) + c_{3}C_{\nu}(\alpha, t)) d\alpha \end{aligned}$$

#### Tracking the population immunity - different sources

 $C_{\nu}(\alpha, t)$ : vaccine-derived immunity for people age =  $\alpha$ 



• 
$$C_H = c_1 C_e + c_2 C_m + c_3 C_{\nu}$$

< ロ > < 同 > < 回 > < 回 > < 回 > <

#### Connecting immunity to transmission

- Immunity dynamics create feedback on infection dynamics: linking functions
- $\rho(C_H/P_H), \psi(C_H/P_H), \phi(C_H/P_H)$



• • = • • = •

$$\partial_{t}S_{H} + \partial_{\alpha}S_{H} = \phi(\widetilde{C}_{H})r_{D}D_{H} + r_{A}A_{H} - \Lambda_{H}(t)S_{H} \\ -\eta(\alpha)\nu_{p}(\alpha,t)S_{H} + wV_{H} - \mu_{H}(\alpha)S_{H}, \\ \partial_{t}E_{H} + \partial_{\alpha}E_{H} = \Lambda_{H}(t)S_{H} - hE_{H} - \mu_{H}(\alpha)E_{H}, \\ \partial_{t}A_{H} + \partial_{\alpha}A_{H} = (1 - \rho(\widetilde{C}_{H}))hE_{H} - \psi(\widetilde{C}_{H})\Lambda_{H}(t)A_{H} \\ + (1 - \phi(\widetilde{C}_{H}))r_{D}D_{H} - r_{A}A_{H} - \mu_{H}(\alpha)A_{H}, \\ \partial_{t}D_{H} + \partial_{\alpha}D_{H} = \rho(\widetilde{C}_{H})hE_{H} + \psi(\widetilde{C}_{H})\Lambda_{H}(t)A_{H} \\ - r_{D}D_{H} - (\mu_{H}(\alpha) + \mu_{D}(\alpha))D_{H}, \\ \partial_{t}V_{H} + \partial_{\alpha}V_{H} = \eta(\alpha)\nu_{p}(\alpha,t)S_{H} - wV_{H} - \mu_{H}(\alpha)V_{H}, \\ \frac{dS_{M}}{dt} = -\Lambda_{M}(t)S_{M} - \sigma E_{M} - \mu_{M}E_{M} \\ \frac{dI_{M}}{dt} = \sigma E_{M} - \mu_{M}I_{M} \\ \partial_{t}C_{e} + \partial_{\alpha}C_{e} = f(\Lambda_{H})(c_{S}S_{H} + c_{E}E_{H} + c_{A}A_{H} + c_{D}D_{H}) \\ - \left(\frac{1}{d_{e}} + \mu_{H}(\alpha) + \mu_{D}(\alpha)\frac{D_{H}}{P_{H}}\right)C_{e}, \\ \partial_{t}C_{w} + \partial_{\alpha}C_{w} = -\left(\frac{1}{d_{m}} + \mu_{H}(\alpha) + \mu_{D}(\alpha)\frac{D_{H}}{P_{H}}\right)C_{w}, \\ \partial_{t}C_{w} + \partial_{\alpha}C_{w} = c_{w}\nu_{b}(\alpha,t)S_{H} - \left(\frac{1}{d_{v}} + \mu_{H}(\alpha) + \mu_{D}(\alpha)\frac{D_{H}}{P_{H}}\right)C_{v}, \\ \end{array}$$

Zhuolin Qu (UTSA)

#### Outlines



Mathematical modeling of malaria with immunity

```
3 Basic reproduction number \mathcal{R}_0
```

Numerical examples

э

イロト イポト イヨト イヨト

- $\mathcal{R}_0$  = the number of cases one case generates within its infectious period, in a totally susceptible population
- $\bullet$  threshold condition for the disease transmission:  $\mathcal{R}_0>1$

<日<br />
<</p>

- $\mathcal{R}_0$  = the number of cases one case generates within its infectious period, in a totally susceptible population
- $\bullet$  threshold condition for the disease transmission:  $\mathcal{R}_0>1$

 $DFE: (\tilde{S}_H, \tilde{E}_H, \tilde{A}_H, \tilde{D}_H, \tilde{V}_H, \tilde{C}_e, \tilde{C}_m, \tilde{C}_\nu) = \\ (\theta(\alpha), 0, 0, 0, 1 - \theta(\alpha), \tilde{C}_e^*(\alpha), \tilde{C}_m^*(\alpha), \tilde{C}_\nu^*(\alpha))$ 

く 目 ト く ヨ ト く ヨ ト

- $\mathcal{R}_0$  = the number of cases one case generates within its infectious period, in a totally susceptible population
- $\bullet$  threshold condition for the disease transmission:  $\mathcal{R}_0>1$

$$DFE: (\tilde{S}_H, \tilde{E}_H, \tilde{A}_H, \tilde{D}_H, \tilde{V}_H, \tilde{C}_e, \tilde{C}_m, \tilde{C}_\nu) = \\ (\theta(\alpha), 0, 0, 0, 1 - \theta(\alpha), \tilde{C}_e^*(\alpha), \tilde{C}_m^*(\alpha), \tilde{C}_\nu^*(\alpha))$$

By analyzing the threshold condition for the stability of DFE  $\ldots$ 

$$\mathcal{R}_0^{\star} = C^{\star} \int_0^{\infty} e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$

- ロ ト - (理 ト - ( ヨ ト - ( ヨ ト - )

- $\mathcal{R}_0$  = the number of cases one case generates within its infectious period, in a totally susceptible population
- $\bullet$  threshold condition for the disease transmission:  $\mathcal{R}_0>1$

$$DFE: (\tilde{S}_{H}, \tilde{E}_{H}, \tilde{A}_{H}, \tilde{D}_{H}, \tilde{V}_{H}, \tilde{C}_{e}, \tilde{C}_{m}, \tilde{C}_{\nu}) = \\ (\theta(\alpha), 0, 0, 0, 1 - \theta(\alpha), \tilde{C}_{e}^{*}(\alpha), \tilde{C}_{m}^{*}(\alpha), \tilde{C}_{\nu}^{*}(\alpha))$$

By analyzing the threshold condition for the stability of DFE  $\ldots$ 

$$\mathcal{R}_{0}^{\star} = C^{\star} \int_{0}^{\infty} e^{-M(\alpha)} \left(\beta_{D} \mathcal{D}(\alpha, 0) + \beta_{A} \mathcal{A}(\alpha, 0)\right) d\alpha$$

$$C^{\star} = \frac{\mu_{H}^{\star} b_{m}^{2} b_{h}^{2} N_{M} N_{H} \beta_{M} \sigma}{(b_{m} N_{M} + b_{h} N_{H})^{2} (\sigma + \mu_{M}) \mu_{M}}, \quad M(\alpha) := \int_{0}^{\alpha} \mu_{H}(a) da$$

$$\mathcal{E}(\alpha, 0) = \int_{0}^{\alpha} e^{-h(\alpha - a)} \theta(a) da,$$

$$\mathcal{D}(\alpha, 0) = \int_{0}^{\alpha} e^{-r_{D}(\alpha - a)} \rho h \mathcal{E}(a, 0) da,$$

$$\mathcal{A}(\alpha, 0) = \int_{0}^{\alpha} e^{-r_{A}(\alpha - a)} \left(h(1 - \rho) \mathcal{E}(a, 0) + r_{D}(1 - \phi) \mathcal{D}(a, 0)\right) da.$$

- $\mathcal{R}_0$  = the number of cases one case generates within its infectious period, in a totally susceptible population
- $\bullet$  threshold condition for the disease transmission:  $\mathcal{R}_0>1$

$$DFE: \quad (\tilde{S}_H, \tilde{E}_H, \tilde{A}_H, \tilde{D}_H, \tilde{V}_H, \tilde{C}_e, \tilde{C}_m, \tilde{C}_\nu) = \\ (\theta(\alpha), 0, 0, 0, 1 - \theta(\alpha), \tilde{C}_e^*(\alpha), \tilde{C}_m^*(\alpha), \tilde{C}_\nu^*(\alpha))$$

By analyzing the threshold condition for the stability of DFE  $\ldots$ 

$$\mathcal{R}_{0}^{\star} = C^{\star} \int_{0}^{\infty} e^{-M(\alpha)} \left(\beta_{D} \mathcal{D}(\alpha, 0) + \beta_{A} \mathcal{A}(\alpha, 0)\right) d\alpha$$

$$C^{\star} = \frac{\mu_{H}^{\star} b_{n}^{2} b_{h}^{2} N_{M} N_{H} \beta_{M} \sigma}{(b_{m} N_{M} + b_{h} N_{H})^{2} (\sigma + \mu_{M}) \mu_{M}}, \quad M(\alpha) := \int_{0}^{\alpha} \mu_{H}(a) da$$

$$\mathcal{E}(\alpha, 0) = \int_{0}^{\alpha} e^{-h(\alpha - a)} \theta(a) da,$$

$$\mathcal{D}(\alpha, 0) = \int_{0}^{\alpha} e^{-r_{D}(\alpha - a)} \rho h \mathcal{E}(a, 0) da, \qquad \text{Interpretation?}$$

$$\mathcal{A}(\alpha, 0) = \int_{0}^{\alpha} e^{-r_{A}(\alpha - a)} \left(h(1 - \rho) \mathcal{E}(a, 0) + r_{D}(1 - \phi) \mathcal{D}(a, 0)\right) da.$$

Zhuolin Qu (UTSA)

$$\mathcal{R}_{0}^{\star} = \left(b_{M}\beta_{M}\frac{\sigma}{\sigma + \mu_{M}}\frac{1}{\mu_{M}}\right)\left(b_{H}\int_{0}^{\infty}\mu_{H}^{*}e^{-M(\alpha)}\left(\beta_{D}\mathcal{D}(\alpha,0) + \beta_{A}\mathcal{A}(\alpha,0)\right)d\alpha\right)$$
$$=:\mathcal{R}_{MH}\times\mathcal{R}_{HM}$$

- $\mathcal{R}_{\textit{MH}}$ : Mosquito  $\rightarrow$  human transmission route
- $\mathcal{R}_{\textit{HM}}$ : Human  $\rightarrow$  mosquito transmission route

э

イロト イボト イヨト イヨト

$$\mathcal{R}_{0}^{\star} = \left(b_{M}\beta_{M}\frac{\sigma}{\sigma+\mu_{M}}\frac{1}{\mu_{M}}\right)\left(b_{H}\int_{0}^{\infty}\mu_{H}^{*}e^{-M(\alpha)}\left(\beta_{D}\mathcal{D}(\alpha,0)+\beta_{A}\mathcal{A}(\alpha,0)\right)d\alpha\right)$$
$$=:\mathcal{R}_{MH}\times\mathcal{R}_{HM}$$

- $\mathcal{R}_{\textit{MH}}$ : Mosquito  $\rightarrow$  human transmission route
- $\mathcal{R}_{\textit{HM}}$ : Human  $\rightarrow$  mosquito transmission route

$$\mathcal{R}_{MH} = b_M \beta_M \frac{\sigma}{\sigma + \mu_M} \frac{1}{\mu_M} \xrightarrow{S_M} E_M \xrightarrow{\sigma} I_M}{\downarrow} \sum_{\substack{\mu_M \\ \mu_M \\ \mu_M$$

э

イロト イボト イヨト イヨト

• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$
  
-  $\mathcal{E}(\alpha, 0) = \int_0^\alpha e^{-h(\alpha-a)} \theta(a) da,$   
-  $\mathcal{D}(\alpha, 0) = \int_0^\alpha e^{-r_D(\alpha-a)} \rho h \mathcal{E}(a, 0) da,$ 

3

イロト イヨト イヨト イヨト

• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} (\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)) d\alpha$$
  
-  $\mathcal{E}(\alpha, 0) = \int_0^\alpha e^{-h(\alpha - a)} \theta(a) da,$   
-  $\mathcal{D}(\alpha, 0) = \int_0^\alpha e^{-r_D(\alpha - a)} \rho h \mathcal{E}(a, 0) da,$ 



• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$

- 
$$\mathcal{E}(lpha,0)=\int_0^lpha e^{-h(lpha-a)} heta(a)\,da,$$

- 
$$\mathcal{D}(\alpha, 0) = \int_0^\alpha e^{-r_D(\alpha-a)} \rho \, h \, \mathcal{E}(a, 0) \, da,$$

•  $h\mathcal{E}(\alpha, 0) = Probability$  an age- $\alpha$  person in  $E_H$ 



• • = • • = •

- $\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$
- $\mathcal{E}(\alpha, 0) = \int_0^\alpha e^{-h(\alpha-a)}\theta(a) \, da$ ,

- 
$$\mathcal{D}(\alpha, 0) = \int_0^\alpha e^{-r_D(\alpha-a)} \rho \, h \, \mathcal{E}(a, 0) \, da,$$

•  $h\mathcal{E}(\alpha, 0) = Probability$  an age- $\alpha$  person in  $E_H$ 



- $\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$
- $\mathcal{E}(\alpha, 0) = \int_0^\alpha e^{-h(\alpha-a)}\theta(a) \, da$ ,

- 
$$\mathcal{D}(\alpha, 0) = \int_0^\alpha e^{-r_D(\alpha-a)} \rho \, h \, \mathcal{E}(a, 0) \, da,$$

•  $h\mathcal{E}(\alpha,0) = Probability$  an age- $\alpha$  person in  $E_H$ 



- $\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$
- $\mathcal{E}(\alpha, 0) = \int_0^\alpha e^{-h(\alpha-a)} \theta(a) \, da$ ,
- $\mathcal{D}(\alpha,0) = \int_0^\alpha e^{-r_D(\alpha-a)} \rho \, h \, \mathcal{E}(a,0) \, da$ ,
- $h\mathcal{E}(\alpha, 0) = Probability$  an age- $\alpha$  person in  $E_H$
- $\mathcal{D}(\alpha, 0) =$  expected time an age- $\alpha$  person spends in  $D_H$



•  $\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$ 

- 
$$\mathcal{E}(lpha,0)=\int_0^lpha e^{-h(lpha-a)} heta(a)\,da,$$

- 
$$\mathcal{D}(\alpha,0) = \int_0^\alpha e^{-r_D(\alpha-a)} \rho \, h \, \mathcal{E}(a,0) \, da,$$

- $h\mathcal{E}(\alpha,0) = Probability$  an age- $\alpha$  person in  $E_H$
- $\mathcal{D}(\alpha, 0) =$  expected time an age- $\alpha$  person spends in  $D_H$
- $E_H \rightarrow D_H$  route only at DFE



• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$

- 
$$\mathcal{A}(\alpha,0) = \int_0^{\alpha} e^{-r_A(\alpha-a)} \Big( h(1-\rho) \mathcal{E}(a,0) + r_D(1-\phi) \mathcal{D}(a,0) \Big) \, da$$

- 
$$h \mathcal{E}(\alpha, 0) =$$
 Probability an age- $\alpha$  person in  $E_H$ 

-  $r_D \mathcal{D}(lpha, \mathbf{0}) =$  Probability an age-lpha person in  $D_H$ 



. . . . . . . .

• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$

- 
$$\mathcal{A}(\alpha,0) = \int_0^\alpha e^{-r_A(\alpha-a)} \Big( h(1-\rho) \mathcal{E}(a,0) + r_D(1-\phi) \mathcal{D}(a,0) \Big) \, da$$

- $h \mathcal{E}(\alpha, 0) =$  Probability an age- $\alpha$  person in  $E_H$
- $r_D \mathcal{D}(\alpha, 0) =$  Probability an age- $\alpha$  person in  $D_H$
- $\mathcal{A}(\alpha, 0) =$  expected time an age- $\alpha$  person spends in  $A_H$



・ 同 ト ・ ヨ ト ・ ヨ ト

• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$

2

<ロト <回ト < 回ト < 回ト -

• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$

-  $\mathcal{R}_{HM,\alpha} = b_H \beta_D \mathcal{D}(\alpha, 0) + b_H \beta_A \mathcal{A}(\alpha, 0)$ 

= new cases produced by infectious age- $\alpha$  people

э

イロト イポト イヨト イヨト

• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$
  
-  $\mathcal{R}_{HM,\alpha} = b_H \beta_D \mathcal{D}(\alpha, 0) + b_H \beta_A \mathcal{A}(\alpha, 0)$   
= new cases produced by infectious age- $\alpha$  people  
-  $\mathcal{R}_{HM} = \int_0^\infty \mathcal{R}_{HM,\alpha} P_H(\alpha) d\alpha$ ,  
where  $P_H(\alpha) = \mu_H^* e^{-M(\alpha)}$ , age distribution of population at DFE

2

<ロト <回ト < 回ト < 回ト -

• 
$$\mathcal{R}_{HM} = b_H \int_0^\infty \mu_H^* e^{-M(\alpha)} \left(\beta_D \mathcal{D}(\alpha, 0) + \beta_A \mathcal{A}(\alpha, 0)\right) d\alpha$$
  
-  $\mathcal{R}_{HM,\alpha} = b_H \beta_D \mathcal{D}(\alpha, 0) + b_H \beta_A \mathcal{A}(\alpha, 0)$   
= new cases produced by infectious age- $\alpha$  people  
-  $\mathcal{R}_{HM} = \int_0^\infty \mathcal{R}_{HM,\alpha} P_H(\alpha) d\alpha$ ,  
where  $P_H(\alpha) = \mu_H^* e^{-M(\alpha)}$ , age distribution of population at DFE

The overall basic reproduction number

$$\mathcal{R}_0 = \sqrt{\mathcal{R}_0^\star} = \sqrt{\mathcal{R}_{MH} \times \mathcal{R}_{HM}}$$

2

イロト イヨト イヨト イヨト

#### Outlines



Mathematical modeling of malaria with immunity

3) Basic reproduction number  $\mathcal{R}_0$ 

4 Numerical examples

э

イロト イポト イヨト イヨト

#### Numerical discretization

Numerical scheme to mimic biological properties...

- positivity preserving
- conservation law of population (people don't disappear magically)

Not too severe time-step constraint

$$\frac{\partial S_H}{\partial t} + \frac{\partial S_H}{\partial \alpha} = -\Lambda_H(t)S_H + \phi r_D D_H + r_A A_H - \mu_H(\alpha)S_H \quad \text{*no vaccine}$$

• uniform grid 
$$(\alpha_k, t_n)$$
,  $\Delta \alpha = \Delta t$   
- LHS  $= \frac{\partial S_H}{\partial t} + \frac{\partial S_H}{\partial \alpha} \rightarrow \frac{S_H^{k+1,n+1} - S_H^{k,n}}{\Delta t}$   
- RHS: "explicit" - "implicit" approach

$$-\Lambda_{H}(t)\underline{S_{H}} + \phi r_{D}D_{H} + r_{A}A_{H} - \mu_{H}(\alpha)\underline{S_{H}}$$

#### Model calibration

- Assumptions
- no disease-induced mortality
- constant demographic structure
- Immunity linking parameters
- susceptibility to developing clinical disease: ho (age, aEIR)
- aEIR: annual entomological inoculation rate



## Immunity profile (age, aEIR)



- low aEIR region (center): flat immunity
- high aEIR region (right): fast decay of maternal immunity after birth and increases as getting older due to repeated exposure

( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( )

#### Impact of immunity feedback



When having dynamic immunity feedback

- As  $\beta_M$  (exposure level) increases,  $A_H$  keeps increasing,  $D_H$  peaks
- stronger exposure, larger feedback onto progression parameters  $\rho, \psi$ , more likely to become  $A_H$  than  $D_H$

#### Impact of immunity feedback



When fixing the population immunity at constant level (low or high)

- as  $\beta_M$  (exposure level) increases, monotone increase in  $D_H$
- worse disease outcome

▲ □ ▶ ▲ □ ▶ ▲ □ ▶

## Immunity feedback onto age-distributions

#### Y-axis - fraction of population: $\widetilde{S}_{H}(\alpha) = S_{H}(\alpha)/P_{H}(\alpha)$ at EE



- fast transition near age zero due to maternal protection
- dynamic immunity creates heterogeneity in the age-distributions
- for fixed immunity, almost homogeneous age-distributions

▲ □ ▶ ▲ □ ▶ ▲ □ ▶

## Immunity feedback onto age-distributions

#### Dynamic immunity with different exposure level



- amount of heterogeneity depends on the exposure level
- low transmission (left): limited boosting in immunity for age < 3
- high transmission (right): more heterogeneity for children < 15

A B b A B b

## Preliminary simulation of RTS,S vaccination

- children complete three doses series around 9 months old
- $\nu_p^0$ : daily per-capita vaccination rate



- drop in the  $D_H$ , but slightly higher  $D_H$  curve when > 3 years old
- reduced exposure delays the development of exposure-acquired immunity

• • = • • = •

#### Modeling immunity to malaria with an age-structured PDE Framework



#### Future work

- model assumptions
- diseased-induced mortality
- growing population in sub-Saharan Africa
- vaccination
- more realistic description of RTS,S vaccine
- boosting dose, optimal strategy
- blood-stage vaccine (boosting  $C_{\nu}$  rather than protection  $V_H$ )
- seasonality
- spatial heterogeneity, human movement

< 回 > < 回 > < 回 > <

#### Acknowledgment

AMS / Mathematics Research Communities - 2021
 "Dynamics of Infectious Diseases: Ecological Models Across Multiple Scales"



Qu Z, Patterson D, Childs L., Edholm C, Ponce J, Prosper O, Zhao L Modeling Immunity to Malaria with an Age-Structured PDE Framework, arXiv

・ロト ・ 同ト ・ ヨト ・ ヨト

#### Acknowledgment

AMS / Mathematics Research Communities - 2021
 "Dynamics of Infectious Diseases: Ecological Models Across Multiple Scales"



Qu Z, Patterson D, Childs L., Edholm C, Ponce J, Prosper O, Zhao L Modeling Immunity to Malaria with an Age-Structured PDE Framework, arXiv Thank you!

Zhuolin Qu (UTSA)

・ロト ・ 同ト ・ ヨト ・ ヨト